4111.TWO Chi Sheng Chemical
- Market cap
- TWD 1.69B
- P/E
- 9.0x
- P/B
- 1.22x
- ROE
- 14.0%
- Dividend yield
- 3.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4111.TWO undervalued?
Graham number4111.TWO trades 30.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chi Sheng Chemical fundamental analysis
No fundamental analysis for Chi Sheng Chemical yet.
Chi Sheng Chemical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chi Sheng Chemical
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerve agents; antihist…
Full company profileChi Sheng Chemical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chi Sheng Chemical annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.04B | 967M | 1.02B | 979M | 1.02B | 1.14B | 1.06B | 1.17B | 1.38B | 1.46B |
| Gross Profit | 346M | 294M | 340M | 323M | 357M | 423M | 343M | 397M | 544M | 576M |
| Operating Income | 103M | 42.8M | 97.5M | 81.6M | 133M | 164M | 61.2M | 98.9M | 199M | 219M |
| EBITDA | 174M | 136M | 180M | 166M | 212M | 237M | 151M | 206M | 282M | 326M |
| Net Income | 81.7M | 42.3M | 72.5M | 59.1M | 80.8M | 154M | 68.7M | 111M | 164M | 197M |
| EPS | 1.43 | 0.74 | 1.27 | 1.03 | 1.41 | 2.69 | 1.21 | 1.94 | 2.75 | 3.29 |
| Balance Sheet | ||||||||||
| Total Assets | 1.48B | 1.50B | 1.52B | 1.49B | 1.66B | 1.80B | 1.77B | 1.75B | 1.94B | 2.04B |
| Total Liabilities | 428M | 458M | 450M | 411M | 559M | 578M | 547M | 475M | 557M | 635M |
| Shareholders' Equity | 1.05B | 1.05B | 1.07B | 1.08B | 1.10B | 1.22B | 1.22B | 1.27B | 1.38B | 1.40B |
| Cash & Short-term Investments | 205M | 226M | 275M | 336M | 252M | 456M | 381M | 336M | 444M | 472M |
| Total Debt | - | - | 173M | 149M | 292M | 290M | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 181M | 114M | 163M | 144M | 139M | 215M | 74.5M | 213M | 275M | 182M |
| Capital Expenditure | 46.8M | 75.4M | 36.9M | 22.8M | 266M | 106M | 102M | 85.2M | 94.5M | 116M |
| Free Cash Flow | 133M | 37.5M | 126M | 121M | -126M | 109M | -27.5M | 128M | 180M | 66.5M |
| Ratios | ||||||||||
| ROE | 7.8% | 4.0% | 6.8% | 5.5% | 7.3% | 12.6% | 5.6% | 8.7% | 11.9% | 14.0% |
| ROA | 5.5% | 2.8% | 4.8% | 4.0% | 4.9% | 8.6% | 3.9% | 6.3% | 8.5% | 9.7% |
| Net Profit Margin | 7.8% | 4.4% | 7.1% | 6.0% | 7.9% | 13.5% | 6.5% | 9.5% | 11.9% | 13.4% |
| Debt to Equity | - | - | 0.16x | 0.14x | 0.27x | 0.24x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chi Sheng Chemical dividends
- Dividend yield
- 3.38%
- Forward dividend
- 1.30 TWD
- Payout ratio
- 34.7%
- Ex-dividend date
- Aug 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 57.0M | 0.95 | 34.7% |
| 2024 | TWD 57.0M | 1.00 | 51.5% |
| 2023 | TWD 68.4M | 1.20 | 99.6% |
| 2022 | TWD 57.0M | 0.99 | 37.0% |
| 2021 | TWD 57.0M | 0.99 | 70.6% |
| 2020 | TWD 57.0M | 1.00 | 96.4% |
| 2019 | TWD 34.2M | 0.60 | 47.2% |
| 2018 | TWD 45.6M | 0.80 | 107.9% |
| 2017 | TWD 45.6M | 0.80 | 55.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1050:1000 on Aug 26, 2025.
Who owns Chi Sheng Chemical
- Insiders 25.24%
- Institutions 0.00%
- Public & others 74.76%
- Shares outstanding 59.8M
- Free float 46.1M
Chi Sheng Chemical company profile
- Company name
- Chi Sheng Chemical
- Ticker
- 4111.TWO
- ISIN
- TW0004111000
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 3, Shih Chen Road, Hukou, Taiwan, 30352
- Phone
- 886 3 598 3811
- Website
- cscp.com.tw
About Chi Sheng Chemical
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerve agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmatics; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatic solutions, food and health food products, functional drinks, skin care products and cosmetics, and veterinary medicinal products. In addition, it provides externally applied medicines, including contact lens, and salt and iodine solutions. Chi Sheng Pharma & Biotech Co., Ltd was founded in 1962 and is headquartered in Hukou, Taiwan.
Chi Sheng Chemical management
4- Dongmao SuChairman & GM
- Hui-Zhen HuangFinance Manager & Accounting Supervisor
- Li Zhu WeiVice President of Technology & Plant Manager
- Guo Ping XieBrand Marketing Manager